Exagen (XGN) Research & Development (2018 - 2026)

Exagen (XGN) has reported Research & Development for 9 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.

• Research & Development for Q1 2026 came in at $1.6 million, up 20.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.5 million (up 16.48% YoY), and the FY2025 annual result was $6.3 million, up 16.35% from the prior year.
• Research & Development was $1.6 million for Q1 2026 at Exagen, down from $1.8 million in the prior quarter.
• Over five years, Research & Development peaked at $2.7 million in Q4 2022 and troughed at $1.1 million in Q1 2024.
• Average Research & Development over 5 years is $1.6 million, with a median of $1.5 million recorded in 2025.
• Year-over-year, Research & Development tumbled 60.16% in 2023 and surged 53.9% in 2024.
• Over 5 years, Research & Development stood at $2.7 million in 2022, then sank by 60.16% to $1.1 million in 2023, then soared by 53.9% to $1.7 million in 2024, then grew by 6.1% to $1.8 million in 2025, then dropped by 11.61% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $1.6 million in Q1 2026, $1.8 million in Q4 2025, and $1.7 million in Q3 2025.